In vitro, altered ESRP1 or ESRP2 levels caused a switch of alternative splicing of FGFR2 between FGFR2-IIIb and FGFR2-IIIc, resulting in changes in tumor cell growth and metastatic potential. Here, FGFR2 is linked to neoplasm.